The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 13, 2012

Filed:

May. 13, 2011
Applicants:

Gavin P. Robertson, Hummelstown, PA (US);

Subbrao V. Madhunapantula, Hershey, PA (US);

Shantu Amin, Union City, NJ (US);

Dhimant Desai, Mechanicsburg, PA (US);

Inventors:

Gavin P. Robertson, Hummelstown, PA (US);

SubbRao V. Madhunapantula, Hershey, PA (US);

Shantu Amin, Union City, NJ (US);

Dhimant Desai, Mechanicsburg, PA (US);

Assignee:

The Penn State Research Foundation, University Park, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A01N 31/00 (2006.01); A61K 31/33 (2006.01); A61K 31/095 (2006.01); C07C 391/00 (2006.01); C07C 395/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R-R1, where R is phenyl, where R1 is (CH)Se—C(═NH)—NH, where R2 is (CH)Se—C(═NH)—NHor R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.


Find Patent Forward Citations

Loading…